Quick Answer
Rapport Therapeutics, Inc. reported Diluted EPS of $2.86 per share (loss) for fiscal year 2025.
Rapport Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.86 | +24.3% |
| 2024 | -$3.78 | +83.6% |
| 2023 | -$23.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.71 | -42.0% | +5.3% |
| June 30, 2025 | -$0.75 | +55.9% | -10.3% |
| March 31, 2025 | -$0.68 | +93.9% | -36.0% |
| September 30, 2024 | -$0.50 | +91.2% | +70.6% |
| June 30, 2024 | -$1.70 | +61.8% | +84.6% |
| March 31, 2024 | -$11.07 | — | -94.2% |
| September 30, 2023 | -$5.70 | — | -28.1% |
| June 30, 2023 | -$4.45 | — | — |
- Rapport Therapeutics, Inc. showed an increase of +24.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Rapport Therapeutics, Inc.’s diluted eps has grown by 87.6% (from $23.10 per share (loss) to $2.86 per share (loss)).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: